PerspectiveInfectious Disease

More than just bugs in spit

See allHide authors and affiliations

Science  08 May 2015:
Vol. 348, Issue 6235, pp. 633-634
DOI: 10.1126/science.aaa2886

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

The development of new drugs for tuberculosis (TB) is not for the faint of heart. In addition to all the typical hurdles to developing a new anti-infective, additional complications result from the complex pathology induced by the disease. Because the bacillus is surrounded by a thick, waxy coat, hit rates in whole-cell screens are typically low; the resulting hits are typically so lipophilic that they do not offer good chemical starting points. Despite extensive research efforts, no TB drug has been developed using target-based approaches. Advances in imaging at both a macroscopic and microscopic level offer new insights and strategies for getting urgently needed new drugs to the clinic.